Arch Biopartners Stock Today
| ARCH Stock | CAD 1.95 0.01 0.51% |
Performance15 of 100
| Odds Of DistressLess than 29
|
Arch Biopartners is selling for under 1.95 as of the 30th of November 2024; that is 0.51 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.95. Arch Biopartners has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Arch Biopartners are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. The company has 64.94 M outstanding shares of which 3.97 K shares are presently shorted by private and institutional investors with about 0.29 days to cover all short positions. More on Arch Biopartners
Moving together with Arch Stock
Moving against Arch Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Arch Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arch Biopartners' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arch Biopartners or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Richard Muruve | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Arch Biopartners' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arch Biopartners' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsArch Biopartners can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arch Biopartners' financial leverage. It provides some insight into what part of Arch Biopartners' total assets is financed by creditors.
| |||||
Arch Biopartners (ARCH) is traded on TSX Venture Exchange in Canada and employs 7 people. Arch Biopartners is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 129.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arch Biopartners's market, we take the total number of its shares issued and multiply it by Arch Biopartners's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arch Biopartners operates under Biotechnology sector and is part of Health Care industry. The entity has 64.94 M outstanding shares of which 3.97 K shares are presently shorted by private and institutional investors with about 0.29 days to cover all short positions.
Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations.
Check Arch Biopartners Probability Of Bankruptcy
Ownership AllocationArch Biopartners holds a total of 64.94 Million outstanding shares. Arch Biopartners shows 19.86 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arch Ownership Details
Arch Biopartners Risk Profiles
Although Arch Biopartners' alpha and beta are two of the key measurements used to evaluate Arch Biopartners' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.0 | |||
| Semi Deviation | 2.14 | |||
| Standard Deviation | 2.68 | |||
| Variance | 7.19 |
Arch Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arch Biopartners without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
Arch Biopartners Corporate Management
Elected by the shareholders, the Arch Biopartners' board of directors comprises two types of representatives: Arch Biopartners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Biopartners' management team and ensure that shareholders' interests are well served. Arch Biopartners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Biopartners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew CFA | Acting Director | Profile | |
| Daniel Muruve | Chief Science Officer | Profile | |
| Paul Beck | CoFounder Scientist | Profile | |
| Justin MacDonald | CoFounder Scientist | Profile |
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.